EXOSOME THERAPY — EXPERIMENTAL BIOLOGIC SUPPORT FOR HEALING & INFLAMMATION.
Stem cell-derived exosomes are extracellular vesicles currently under active investigation for their potential to modulate inflammation, facilitate cellular repair, and enhance immunological homeostasis. At EverHealth Institute in Orlando, FL, exosome therapy is offered strictly as an experimental service under direct physician supervision.
Preliminary human studies — including research in inflammatory lung illness, autoimmune disorders, and orthopedic recovery — indicate that exosome-based therapy may diminish systemic inflammatory biomarkers including CRP, IL-6, and TNF-α when administered systemically.
HOW EXOSOMES MAY WORK.
Exosomes appear to modulate inflammatory signaling, lower oxidative stress, help maintain endothelial stability, and encourage intercellular communication important for healing. Initial human studies indicate possible advantages — though a significant portion of this research remains in early and exploratory stages.
Inflammatory Modulation
Exosomes carry proteins, lipids, and microRNAs that may suppress pro-inflammatory cytokines including TNF-α, IL-6, and CRP — reducing systemic and localized inflammatory burden.
Cellular Repair Signaling
By delivering targeted growth factors and genetic signals into recipient cells, exosomes may activate repair pathways, support tissue regeneration, and improve local healing environments.
Immune Homeostasis
Exosome signaling may support a more balanced immune response — reducing chronic overactivation while supporting the immune functions necessary for healthy tissue repair.
Endothelial Stability
Early data suggests exosomes may support vascular endothelial integrity, promoting healthy blood vessel function and improving circulatory delivery to healing tissues.
CONDITIONS CURRENTLY BEING RESEARCHED.
Exosomes are being actively studied across a range of conditions. These are research-based applications — not approved medical treatments. Outcomes vary, and no therapeutic claims can be made at this time.
Systemic Inflammatory States
Post-infectious inflammation and chronic systemic inflammatory conditions — including autoimmune-related disease and inflammatory markers such as CRP and IL-6.
Orthopedic Recovery & Joint Health
Tendinopathy, joint degeneration, soft-tissue injury recovery, and post-procedural repair — including investigational local injection protocols.
Pulmonary Inflammatory Disease
Including inhaled exosome research and systemic delivery in inflammatory lung conditions. Early data shows possible reductions in pulmonary inflammatory markers.
Tissue Repair & Wound Recovery
Cellular signaling support for wound healing, tissue regeneration, and recovery from injury — primarily through local or targeted delivery methods.
Immune Modulation
Investigational use in autoimmune conditions, immune dysregulation, and conditions where overactive inflammatory signaling drives tissue damage.
Degenerative Joint Disease
Early human data suggests possible decreases in inflammatory indicators and clinical improvement in osteoarthritis and chronic joint conditions.
SUPPORTING LITERATURE & EXOSOMES VS. STEM CELLS.
Human studies directly involving exosomes remain limited — which makes the parallel UC-MSC evidence clinically and ethically important context for understanding what exosome-mediated signaling may achieve.
Key Published Studies
Bone-marrow–derived exosomes demonstrated significant drops in CRP, ferritin, and other inflammatory markers following systemic distribution.
Randomized, placebo-controlled trial showed reductions in TNF-α and IL-6 following UC-MSC infusion in rheumatoid arthritis.
Demonstrated decreased systemic CRP and cytokine levels following MSC infusion in inflammatory lung illness.
MSC therapy for osteoarthritis showed improved cartilage outcomes and reduced systemic inflammatory signals.
LOCAL VS. SYSTEMIC ADMINISTRATION.
Exosomes can be delivered via local targeted injection or systemic IV administration. Each approach has distinct evidence, applications, and oversight requirements at our Orlando, FL practice.
Investigational Use
Research is ongoing in joint and soft-tissue applications with localized delivery under sterile technique and physician guidance.
Investigational Use
Early-stage human data suggests potential modulation of inflammatory biomarkers. Evidence remains limited and largely exploratory. All systemic use requires:
SOURCING, SAFETY STANDARDS & WHAT TO EXPECT.
At EverHealth in Orlando, FL, clinical-grade EV products are sourced exclusively from licensed GMP facilities. Every patient undergoes a structured medical process before treatment begins.
Possible Side Effects
Comprehensive physician consultation — medical history, risk profile review, medication assessment, and discussion of realistic expectations
Laboratory baseline testing and eligibility screening prior to any treatment
Full informed consent with transparent discussion of what is and is not known about exosome therapy
Physician-supervised administration with safety monitoring and follow-up assessment at defined intervals
Exosome therapy at EverHealth Institute is investigational and is not FDA-approved to diagnose, treat, cure, or prevent any disease. Results vary. Risks and alternatives are discussed thoroughly prior to treatment. At our Orlando, FL practice, exosomes are provided only as an experimental service from GMP-tested, clinically validated suppliers under full physician supervision and informed consent.
Frequently Asked Questions
Is exosome therapy FDA-approved?
No. There are currently no FDA-approved exosome products. All use is investigational.
Are exosomes the same as stem cells?
No. Exosomes are cell-derived vesicles, not live stem cells.
Where do exosomes come from?
We work only with vetted GMP suppliers who provide validated sourcing and testing documentation.
Can exosome therapy cure disease?
No claims of cure or disease treatment can be made. Use is exploratory.
Who should not receive exosomes?
Generally excluded populations include:
• Active systemic infection
• Pregnancy or breastfeeding
• Active cancer under treatment (unless approved by oncology)
• Severe autoimmune flares
• Known allergy to product components
Experimental UC Exosome IV Prot…
Why Patients Choose EverHealth
• Physician-led care
• Ethical and transparent risk communication
• Evidence-anchored protocols
• Gold-standard sourcing quality
• Advanced biomarker monitoring
• Integration with your total longevity plan
We are proud to be at the forefront of responsible, safety-first regenerative medicine research access, ensuring that innovation is delivered with uncompromising medical standards.